SecBot SecBot
SECBOTREPLAY Home › Report › REPL

REPL · Replimune presented its BLA resubmission for RP1 (vusolimogene…

Replimune Group, Inc. · 8-K filed Jul 30, 2026 at 08:06 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 30, 2026 at 08:06 ET

Replimune presented its BLA resubmission for RP1 (vusolimogene oderparepvec, TUDRIQEV) in combination with nivolumab to the FDA advisory committee for advanced melanoma. The IGNYTE Phase 2 data showed a 33.6% ORR (16.4% CR), median DOR of 24.8 months, and a 3-year OS rate of 47.8% with a manageable safety profile. The FDA's initial clinical review had already recommended accelerated approval, making today's advisory committee vote a pivotal catalyst for the stock.

  • IGNYTE Phase 2 ORR: 33.6% (95% CI: 25.8, 42) with 16.4% complete response rate
  • Median duration of response: 24.8 months (95% CI: 14.8, NE)
  • 3-year overall survival rate: 47.8% (median OS 32.9 months)
  • No treatment-related Grade 5 adverse events; mainly Grade 1-2 toxicities

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access